CNBX — CNBX Pharmaceuticals Balance Sheet
0.000.00%
- $0.01m
- $1.37m
- $0.13m
Annual balance sheet for CNBX Pharmaceuticals, fiscal year end - August 31st, USD millions except per share, conversion factor applied.
2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 0.778 | 1.39 | 0.118 | 0.13 | 0.026 |
Net Total Receivables | 0 | — | — | — | — |
Prepaid Expenses | |||||
Total Current Assets | 0.93 | 1.59 | 0.198 | 0.224 | 0.031 |
Net Property, Plant And Equipment | 0.863 | 0.643 | 0.437 | 0.275 | 0 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Total Assets | 2.22 | 3.08 | 0.811 | 0.499 | 0.031 |
Payable / Accrued | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.455 | 1.27 | 2.44 | 2.52 | 2.51 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.455 | 1.27 | 2.44 | 2.52 | 2.51 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 1.76 | 1.81 | -1.63 | -2.02 | -2.48 |
Total Liabilities & Shareholders' Equity | 2.22 | 3.08 | 0.811 | 0.499 | 0.031 |
Total Common Shares Outstanding |